Clinical Data, Inc., a biotechnology company, engages in the development and commercialization of therapeutic products. Its principal product includes Viibryd, a selective serotonin reuptake inhibitor and serotonin 1A (5-HT1A) receptor partial agonist for the treatment of major depressive disorder (MDD) in adults. The company received marketing approval from the U.S. Food and Drug Administration in January 2011 for the treatment of MDD in adults. Clinical Datas other product comprises Stedivaze, a pharmacologic stress agent in Phase III development for use during myocardial perfusion imaging. Stedivaze is designed to expand the blood vessels of the heart to make it easier to get an image of those blood vessels, and is intended for use in patients with coronary artery disease who can't undergo exercise stress testing. The company also has other drug candidates in development for various therapeutic areas, including asthma, ophthalmology, and diabetes. Clinical Data was founded in 1969 and is headquartered in Newton, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for CLDA